2928515-21-1
Chemical Structure
Peluntamig
Synonym(s): PT-217
- CAS No.: 2928515-21-1
- Formula:N/A
- Molecular Weight:(145.027 kDa)
SMILES: [Peluntamig]
Biological Activity: Peluntamig (PT-217) is a bispecific antibody targeting DLL3 and CD47. The antibody arms of Peluntamig specifically bind to DLL3 on small cell lung cancer tumor cells while blocking the CD47-SIRPa interaction, thereby effectively stimulating macrophage phagocytosis and inducing NK cell-mediated cytotoxicity. Peluntamig exhibits significant anti-tumor activity against small cell lung cancer and also has favorable safety profiles. Peluntamig can be used in a variety of tumor-related studies including those on small cell lung cancer and L1210 leukemia[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Peluntamig | 99.9% | Peluntamig (PT-217) is a bispecific antibody targeting DLL3 and CD47. The antibody arms of Peluntamig specifically bind to DLL3 on small cell lung cancer tumor cells while blocking the CD47-SIRPa interaction, thereby effectively stimulating macrophage phagocytosis and inducing NK cell-mediated cytotoxicity. Peluntamig exhibits significant anti-tumor activity against small cell lung cancer and also has favorable safety profiles. Peluntamig can be used in a variety of tumor-related studies including those on small cell lung cancer and L1210 leukemia. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Corica D A, Bell S D, Zhao L, et al. The Era of Precision Medicine: Advancing Treatment Paradigms for Small Cell Lung Cancer[J]. Cancers, 2025, 17(11): 1847.
- [2]. Gale G R, Atkins L M, Schwartz P, et al. Potentiating action of 5-fluorouracil when used in combination with platinum compounds and cyclophosphamide in treatment of advanced L1210 leukemia[J]. Bioinorganic Chemistry, 1978, 8(5): 445-451.
Keywords
